NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading GOSS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, which adds uncertainty to its long-term prospects.
The market appears to price in a justified valuation that is cheap compared to peers. However, there is an expectations gap, indicating that investors may anticipate some challenges ahead.
Fundamentals are likely to remain under pressure due to a high probability of an earnings miss in the near term. Recent financial performance has been neutral, but the company has shown some positive revenue growth from collaborations.
The thesis hinges on the performance of sector bellwethers and GOSS's ability to manage its capital allocation effectively. Additionally, the upcoming NDA submission for seralutinib will be a critical event to monitor.
Over the next 1 to 3 years, GOSS's path will depend significantly on its execution of management priorities and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings results will show if revenue growth is getting better or worse. This will affect investor feelings.
Confirms one read:Q2 earnings report shows revenue growth above 5% year over year.
Confirms the other:Q2 earnings report shows revenue growth below 0% year over year.
Why it matters: Submitting the NDA is key for Gossamer's growth in pulmonary arterial hypertension. It could open new revenue streams.
Confirms:A press release confirms the NDA submission for seralutinib in PAH.
Disproves:No news or delay in the NDA submission timeline.
Why it matters: Revenue growth is crucial for Gossamer's recovery. It shows market demand and company health.
Confirms one read:Revenue growth reported above 5% year over year in Q2 2026.
Confirms the other:Revenue growth reported below 0% year over year in Q2 2026.
Why it matters: How Gossamer uses its money can impact its stability and growth.
Confirms one read:The company shares a clear plan for using money from the convertible notes.
Confirms the other:The company fails to provide clarity on the use of proceeds, raising concerns.
Why it matters: A buyback program can signal confidence in the company's value and improve share price.
Confirms:A formal announcement about the share buyback program is coming.
Disproves:No announcement made by the end of Q3 2026.
Why it matters: Growth in revenue from this partnership is key for Gossamer's finances.
Confirms:Revenue from the Chiesi collaboration rises from $17.0 million in Q1 2026.
Disproves:Revenue from the Chiesi collaboration falls or stays the same from Q1 2026.
Why it matters: Good results could show seralutinib works well and help investor trust.
Confirms:The company shares more good results from the PROSERA study.
Disproves:The company reports bad results or no new updates from the PROSERA study.
